健康人和变应性鼻炎患者口鼻呼出气一氧化氮无创检测研究

Noninvasive measurement of nasal NO and fractional exhaled NO in healthy people and patients with allergic rhinitis

目的 检测健康人和变应性鼻炎（allergic rhinitis,AR）患者口、鼻呼出气一氧化氮浓度（分别用FENO和NNO表示）,并探讨其临床意义.方法 健康志愿者96名,不伴哮喘的中-重度持续性AR患者51例,用瑞典NIOX MINO仪器无创检测FENO和NNO浓度.以SPSS 13.0统计软件进行数据处理.结果 健康人的NNO浓度为245.0[189.8;331.3] ppb（中位数[25分位数;75分位数],下同）,FENO浓度为14.0[10.0;18.0] ppb.AR患者的NNO浓度为304.0[179.5;397.5] ppb,FENO浓度为21.0[16.0;40.5]ppb.与健康人相比,AR患者的NNO浓度升高,但差异无统计学意义（Z=1.349,P=0.177）;FENO浓度亦升高,且差异有统计学意义（Z =5.555,p=0.000）.结论 中-重度持续性AR患者在无哮喘症状时FENO浓度已经显著升高,提示应该积极治疗AR预防发展成哮喘.

Objective To measure the nasal nitric oxide （NNO） and fractional exhaled nitric oxide （FENO） in healthy people and patients with allergic rhinitis （AR）,and to discuss the clinical significance of the results.Methods Ninety-six healthy volunteers and 51 patients with moderate-severe persistent AR,but without asthma,were enrolled.NNO and FENO concentrations were measured noninvasively by using of NIOX MINO （Aerocrine AB,Solna,Sweden）.SPSS 13.0 software was used to analyze the data.Results The concentration of NNO in healthy people was 245.0 [189.8 ;331.3] ppb （median [25th percentile ; 75th percentile],the followings were same as）.The concentration of FENO was 14.0 [10.0; 18.0] ppb.The concentration of NNO in patients with AR was 304.0 [179.5 ; 397.5] ppb.The concentration of FENO was 21.0[16.0; 40.5] ppb.The concentration of NNO in the AR patients was higher than that in the healthy persons,but the difference did not reach statistical significance （Z =1.349,P =0.177）.On the other hand,FENO concentrations were significantly increased in patients compared with concentrations in healthy persons （Z =5.555,P =0.000）.Conclusions FENO concentrations of patients with moderate-severe persistent AR are increased significantly even though the patients do not have typical symptoms of asthma.This finding suggests that AR patients should be treated actively in order to prevent asthma from developing in them.